Page last updated: 2024-10-15

thiolactomycin

Description

thiolactomycin: from actinomycetes; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135403829
SCHEMBL ID13332161
SCHEMBL ID12099108
MeSH IDM0107685

Synonyms (45)

Synonym
(r)-(+)-thiolactomycin
(+)-thiolactomycin
EU-0100908
LOPAC0_000908
82079-32-1
thiolactomycin
(4-r)(2e,5e)-2,4,6-trimethyl-3-hydroxy-2,5,7-octatriene-4-thiolide
TLM ,
antibiotic 2-200
2(5h)-thiophenone, 3,5-dimethyl-4-hydroxy-5-(2-methyl-1,3-butadienyl)-, (r-(e))-
(5r)-4-hydroxy-3,5-dimethyl-5-[(1e)-2-methylbuta-1,3-dienyl]thiophen-2-one
brn 4423670
4-hydroxy-3,5-dimethyl-5-(2-methyl-buta-1,3-dienyl)-5h-thiophen-2-one
DB04302
1FJ4
2(5h)-thiophenone, 4-hydroxy-3,5-dimethyl-5-(2-methyl-1,3-butadienyl)-, (s-(e))-
(r-(e))-3,5-dimethyl-4-hydroxy-5-(2-methyl-1,3-butadienyl)-2(5h)-thiophenone
NCGC00094221-01
NCGC00094221-02
2VB8
(2r)-5-hydroxy-2,4-dimethyl-2-[(1e)-2-methylbuta-1,3-dien-1-yl]-2,3-dihydrothiophen-3-one
T 9567
[r-(e)]-4-hydroxy-3,5-dimethyl-5-(2-methyl-1,3-butadienyl)-2(5h)-thiophenone
(5r)-thiolactomycin
(2r)-5-hydroxy-2,4-dimethyl-2-[(1e)-2-methylbuta-1,3-dienyl]thiophen-3-one
HMS3262F18
CCG-204990
LP00908
4C6X
SCHEMBL13332161
tox21_500908
NCGC00261593-01
SCHEMBL12099108
DTXSID6041139
AKOS027325299
sr-01000076067
SR-01000076067-1
(5r)-4-hydroxy-3,5-dimethyl-5-[(1e)-2-methylbuta-1,3-dien-1-yl]thiophen-2(5h)-one
Q27095124
SDCCGSBI-0050883.P002
(r,e)-4-hydroxy-3,5-dimethyl-5-(2-methylbuta-1,3-dien-1-yl)thiophen-2(5h)-one
thiolactomycine
(5r)-4-hydroxy-3,5-dimethyl-5-[(1e)-2-methylbuta-1,3-dien-1-yl]-2,5-dihydrothiophen-2-one
HY-122394
CS-0085000

Research Excerpts

Overview

Thiolactomycin is a new broad-spectrum antibiotic, active in vitro against many species of Gram-positive cocci, Enterobacteriaceae, Haemophilus, acid-fast bacteria and anaerobic bacteria.

ExcerptReference
"Thiolactomycin is a natural product inhibitor has shown good inhibitory activity against MTB-KasA."( In Silico Drug Design of Thiolactomycin Derivatives Against Mtb-KasA Enzyme to Inhibit Multidrug Resistance of Mycobacterium tuberculosis.
Durairaj, DR; Shanmughavel, P, 2019
)
"Thiolactomycin (TLM) is a natural product inhibitor of KasA, the β-ketoacyl synthase A from Mycobacterium tuberculosis. "( Thiolactomycin-based β-ketoacyl-AcpM synthase A (KasA) inhibitors: fragment-based inhibitor discovery using transient one-dimensional nuclear overhauser effect NMR spectroscopy.
Bommineni, GR; Kapilashrami, K; Kim, P; Lai, CT; Machutta, CA; Picart, F; Simmerling, C; Tonge, PJ, 2013
)
"Thiolactomycin is an inhibitor of Type II fatty acid synthase which is found in plants and most prokaryotes, but not an inhibitor of Type I fatty acid synthase in mammals."( Analogues of thiolactomycin as potential anti-malarial and anti-trypanosomal agents.
Berry, C; Brun, R; Gilbert, IH; Harwood, JL; Jones, SM; Urch, JE, 2004
)
"Thiolactomycin is a new broad-spectrum antibiotic, active in vitro against many species of Gram-positive cocci, Enterobacteriaceae, Haemophilus, acid-fast bacteria and anaerobic bacteria. "( Thiolactomycin, a new antibiotic. III. In vitro antibacterial activity.
Endo, H; Miyakawa, S; Noto, T; Oishi, H; Okazaki, H, 1982
)
"Thiolactomycin (TLM) is a unique thiolactone that has been shown to exhibit anti-mycobacterial activity by specifically inhibiting fatty acid and mycolic acid biosynthesis."( Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis.
Alland, D; Baulard, AR; Besra, GS; Brennan, PJ; Douglas, JD; Dover, LG; Guy, MR; Jacobs, WR; Kremer, L; Lakey, JH; Minnikin, DE; Morehouse, C, 2000
)
"Thiolactomycin (TLM) is an antibiotic that inhibits bacterial type II fatty acid synthesis at the condensing enzyme step, and beta-ketoacyl-acyl carrier protein synthase I (FabB) is the relevant target in Escherichia coli. "( A missense mutation in the fabB (beta-ketoacyl-acyl carrier protein synthase I) gene confers tiolactomycin resistance to Escherichia coli.
Jackowski, S; Price, AC; Rock, CO; White, SW; Zhang, YM, 2002
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (26)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency2.05250.003245.467312,589.2998AID1705; AID2517; AID2572
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency11.22020.004023.8416100.0000AID485290
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency19.21190.125919.1169125.8920AID2353; AID2549; AID2708
endonuclease IVEscherichia coliPotency3.16230.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency37.68580.100020.879379.4328AID588453
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.31620.540617.639296.1227AID2364; AID2528
DNA polymerase betaHomo sapiens (human)Potency25.11890.022421.010289.1251AID485314
DNA polymerase eta isoform 1Homo sapiens (human)Potency14.12540.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency15.84890.050127.073689.1251AID588590
M-phase phosphoprotein 8Homo sapiens (human)Potency50.11870.177824.735279.4328AID488949
Glutamate receptor 1Rattus norvegicus (Norway rat)Potency1.99530.01418.602439.8107AID2572
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency1.99530.001551.739315,848.9004AID2572
Glutamate receptor 3Rattus norvegicus (Norway rat)Potency1.99530.01418.602439.8107AID2572
Glutamate receptor 4Rattus norvegicus (Norway rat)Potency1.99530.01418.602439.8107AID2572
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty acid synthase Rattus norvegicus (Norway rat)IC50 (µMol)951.00000.05000.05000.0500AID697057
DNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)IC50 (µMol)1.00000.05502.967710.0000AID1370986
Fatty acid synthaseHomo sapiens (human)IC50 (µMol)240.00000.00772.46245.8000AID259393; AID697058
3-oxoacyl-[acyl-carrier-protein] synthase 3Mycobacterium tuberculosis H37RvIC50 (µMol)55.33334.00004.00004.0000AID259390; AID259392; AID309336
3-oxoacyl-[acyl-carrier-protein] synthase 2Mycobacterium tuberculosis H37RvIC50 (µMol)6.00006.00006.00006.0000AID259391
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, BETA-KETOACYL-[ACYL CARRIER PROTEIN] SYNTHASE IEscherichia coliKd26.000026.000026.000026.0000AID977611
Chain A, 3-OXOACYL-[ACYL-CARRIER-PROTEIN] SYNTHASE 1Escherichia coliKd25.000025.000025.000025.0000AID977611
Chain A, 3-OXOACYL-[ACYL-CARRIER-PROTEIN] SYNTHASE 1Escherichia coliKd25.000025.000025.000025.0000AID977611
Chain B, 3-OXOACYL-[ACYL-CARRIER-PROTEIN] SYNTHASE 1Escherichia coliKd25.000025.000025.000025.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (28)

Processvia Protein(s)Taxonomy
fatty acid metabolic process3-oxoacyl-[acyl-carrier-protein] synthase 3Escherichia coli K-12
fatty acid biosynthetic process3-oxoacyl-[acyl-carrier-protein] synthase 3Escherichia coli K-12
small molecule metabolic process3-oxoacyl-[acyl-carrier-protein] synthase 3Escherichia coli K-12
fatty acid biosynthetic process3-oxoacyl-[acyl-carrier-protein] synthase 1Escherichia coli K-12
monounsaturated fatty acid biosynthetic process3-oxoacyl-[acyl-carrier-protein] synthase 1Escherichia coli K-12
fatty acid biosynthetic process3-oxoacyl-[acyl-carrier-protein] synthase 1Escherichia coli K-12
small molecule metabolic process3-oxoacyl-[acyl-carrier-protein] synthase 1Escherichia coli K-12
telomere maintenanceDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA repairDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
base-excision repairDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
base-excision repair, gap-fillingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA catabolic processDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA recombinationDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
regulation of apoptotic processDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
regulation of mRNA stabilityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
positive regulation of gene expression via chromosomal CpG island demethylationDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
cell redox homeostasisDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
negative regulation of DNA-templated transcriptionDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
telomere maintenance via base-excision repairDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
osteoblast differentiationFatty acid synthaseHomo sapiens (human)
glandular epithelial cell developmentFatty acid synthaseHomo sapiens (human)
fatty acid metabolic processFatty acid synthaseHomo sapiens (human)
fatty acid biosynthetic processFatty acid synthaseHomo sapiens (human)
inflammatory responseFatty acid synthaseHomo sapiens (human)
ether lipid biosynthetic processFatty acid synthaseHomo sapiens (human)
neutrophil differentiationFatty acid synthaseHomo sapiens (human)
monocyte differentiationFatty acid synthaseHomo sapiens (human)
mammary gland developmentFatty acid synthaseHomo sapiens (human)
modulation by host of viral processFatty acid synthaseHomo sapiens (human)
cellular response to interleukin-4Fatty acid synthaseHomo sapiens (human)
establishment of endothelial intestinal barrierFatty acid synthaseHomo sapiens (human)
fatty-acyl-CoA biosynthetic processFatty acid synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (42)

Processvia Protein(s)Taxonomy
3-oxoacyl-[acyl-carrier-protein] synthase activity3-oxoacyl-[acyl-carrier-protein] synthase 3Escherichia coli K-12
acyltransferase activity3-oxoacyl-[acyl-carrier-protein] synthase 3Escherichia coli K-12
beta-ketoacyl-acyl-carrier-protein synthase III activity3-oxoacyl-[acyl-carrier-protein] synthase 3Escherichia coli K-12
3-oxoacyl-[acyl-carrier-protein] synthase activity3-oxoacyl-[acyl-carrier-protein] synthase 1Escherichia coli K-12
acyltransferase activity3-oxoacyl-[acyl-carrier-protein] synthase 1Escherichia coli K-12
acyltransferase activity, transferring groups other than amino-acyl groups3-oxoacyl-[acyl-carrier-protein] synthase 1Escherichia coli K-12
DNA bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
damaged DNA bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
double-stranded telomeric DNA bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
transcription coactivator activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
transcription corepressor activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
RNA bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA-(apurinic or apyrimidinic site) endonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
endonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA endonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
RNA-DNA hybrid ribonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
phosphodiesterase I activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
uracil DNA N-glycosylase activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
protein bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
phosphoric diester hydrolase activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
3'-5'-DNA exonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
double-stranded DNA exodeoxyribonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
3'-5' exonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
oxidoreductase activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
site-specific endodeoxyribonuclease activity, specific for altered baseDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
chromatin DNA bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
metal ion bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
class II DNA-(apurinic or apyrimidinic site) endonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
phosphodiesterase activity, acting on 3'-phosphoglycolate-terminated DNA strandsDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
DNA-(abasic site) bindingDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
double-stranded DNA 3'-5' DNA exonuclease activityDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
RNA bindingFatty acid synthaseHomo sapiens (human)
[acyl-carrier-protein] S-acetyltransferase activityFatty acid synthaseHomo sapiens (human)
[acyl-carrier-protein] S-malonyltransferase activityFatty acid synthaseHomo sapiens (human)
3-oxoacyl-[acyl-carrier-protein] synthase activityFatty acid synthaseHomo sapiens (human)
3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activityFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseHomo sapiens (human)
protein bindingFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxymyristoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxydecanoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseHomo sapiens (human)
fatty acyl-[ACP] hydrolase activityFatty acid synthaseHomo sapiens (human)
phosphopantetheine bindingFatty acid synthaseHomo sapiens (human)
cadherin bindingFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxybutanoyl-[acyl-carrier-protein] hydratase activityFatty acid synthaseHomo sapiens (human)
(3R)-3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase activityFatty acid synthaseHomo sapiens (human)
enoyl-[acyl-carrier-protein] reductase (NADPH) activityFatty acid synthaseHomo sapiens (human)
fatty acid synthase activityFatty acid synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
cytoplasm3-oxoacyl-[acyl-carrier-protein] synthase 3Escherichia coli K-12
cytosol3-oxoacyl-[acyl-carrier-protein] synthase 3Escherichia coli K-12
cytoplasm3-oxoacyl-[acyl-carrier-protein] synthase 1Escherichia coli K-12
cytosol3-oxoacyl-[acyl-carrier-protein] synthase 1Escherichia coli K-12
cytosol3-oxoacyl-[acyl-carrier-protein] synthase 1Escherichia coli K-12
cytosolFatty acid synthase Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
chromosome, telomeric regionDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
nucleusDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
nucleoplasmDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
nucleolusDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
cytoplasmDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
mitochondrionDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
endoplasmic reticulumDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
centrosomeDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
ribosomeDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
nuclear speckDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
perinuclear region of cytoplasmDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
nucleusDNA-(apurinic or apyrimidinic site) endonucleaseHomo sapiens (human)
Golgi apparatusFatty acid synthaseHomo sapiens (human)
cytosolFatty acid synthaseHomo sapiens (human)
plasma membraneFatty acid synthaseHomo sapiens (human)
membraneFatty acid synthaseHomo sapiens (human)
melanosomeFatty acid synthaseHomo sapiens (human)
glycogen granuleFatty acid synthaseHomo sapiens (human)
extracellular exosomeFatty acid synthaseHomo sapiens (human)
cytoplasmFatty acid synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (87)

Assay IDTitleYearJournalArticle
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID388057Antibacterial activity against Haemophilus influenzae IID983 by agar dilution method2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Synthesis and biological activity of enantiomeric pairs of 5-[(E)-cycloalk-2-enylidenemethyl]thiolactomycin congeners.
AID427048Antibacterial activity against Escherichia coli after 20 hrs by twofold serial broth dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Antimicrobial natural products as beta-ketoacyl-acyl carrier protein synthase III inhibitors.
AID1625608Antibacterial activity against methicillin-resistant Staphylococcus aureus BAA 1762 infected in Swiss Webster mouse assessed as increase in survival rate at 100 mg/kg, sc administered 1 and 25 hrs post infection measured twice a day for 5 days relative to2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity.
AID242291Inhibitory concentration against purified human fatty acid synthase activity in ZR-75-1 breast cancer cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase.
AID380448Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis CL8516 after 20 hrs2006Journal of natural products, Mar, Volume: 69, Issue:3
Discovery of bacterial fatty acid synthase inhibitors from a Phoma species as antimicrobial agents using a new antisense-based strategy.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID248479Inhibitory concentration against MCF-7 breast cancer cells in XTT assay (non radioactive assay)2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase.
AID259388Inhibitory activity against FabB from Escherichia coli ANSI2006Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1
Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli.
AID590137Inhibition of Plasmodium falciparum W2 recombinant falcipain-22011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Novel thiolactone-isatin hybrids as potential antimalarial and antitubercular agents.
AID1331257Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 5 days by micro plate alamar blue assay2017Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1
Synthesis, screening and docking analysis of hispolon analogs as potential antitubercular agents.
AID248187Inhibitory concentration against fatty acid synthesis in MCF-7 breast cancer cells2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase.
AID308069Antimicrobial activity against Moraxella catarrhalis ATCC 252382007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
Synthesis and biological activity of enantiomeric pairs of 5-vinylthiolactomycin congeners.
AID1370986Inhibition of human APE1 preincubated for 15 mins followed by substrate addition by HTS assay2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Inhibitors of nuclease and redox activity of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1).
AID1625605Binding affinity to Staphylococcus aureus FabF C165Q mutant expressed in Escherichia coli BL21 (DE3) PlysS cells by intrinsic tryptophan fluorescence quenching-based fluorimetric method2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity.
AID308068Antimicrobial activity against Staphylococcus aureus2007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
Synthesis and biological activity of enantiomeric pairs of 5-vinylthiolactomycin congeners.
AID590138Antitubercular activity against Mycobacterium tuberculosis H37Rv at 1 ug/ml by BACTEC radiometric susceptibility assay2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Novel thiolactone-isatin hybrids as potential antimalarial and antitubercular agents.
AID259391Inhibitory activity against KasB from Mycobacterium tuberculosis H37Rv2006Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1
Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli.
AID259389Inhibitory activity against FabH from Escherichia coli ANSI2006Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1
Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli.
AID345870Antimalarial activity against chloroquine-resistant Plasmodium falciparum D6 by [3H]hypoxanthine uptake2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Targeting the fatty acid biosynthesis enzyme, beta-ketoacyl-acyl carrier protein synthase III (PfKASIII), in the identification of novel antimalarial agents.
AID1625601Antibacterial activity against methicillin-sensitive Staphylococcus aureus RN4220 after 18 to 24 hrs by Alamar blue dye-based colorimetric assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity.
AID393129Antimicrobial activity against Enterococcus faecalis KCTC 2011 after 20 hrs by twofold serial broth dilution method2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Novel E. coli beta-ketoacyl-acyl carrier protein synthase III inhibitors as targeted antibiotics.
AID1625604Binding affinity to Staphylococcus aureus wild type FabF expressed in Escherichia coli BL21 (DE3) PlysS cells by intrinsic tryptophan fluorescence quenching-based fluorimetric method2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity.
AID1653413Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by BACTEC radiometric growth assay2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Insights of synthetic analogues of anti-leprosy agents.
AID259393Inhibitory activity against human FAS12006Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1
Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli.
AID393128Antimicrobial activity against Staphylococcus aureus KCTC 1621 after 20 hrs by twofold serial broth dilution method2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Novel E. coli beta-ketoacyl-acyl carrier protein synthase III inhibitors as targeted antibiotics.
AID259386Inhibitory activity against Escherichia coli ANSI2006Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1
Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli.
AID590139Antitubercular activity against Mycobacterium tuberculosis H37Rv at 10 ug/ml by BACTEC radiometric susceptibility assay2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Novel thiolactone-isatin hybrids as potential antimalarial and antitubercular agents.
AID634362Inhibition of Staphylococcus aureus recombinant GST-tagged KAS3 expressed in Escherichia coli (DE3) at 1:10 protein to drug ratio by fluorescence quenching analysis2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Discovery of novel selective inhibitors of Staphylococcus aureus β-ketoacyl acyl carrier protein synthase III.
AID590141Antitubercular activity against Mycobacterium tuberculosis H37Rv by LORA assay2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Novel thiolactone-isatin hybrids as potential antimalarial and antitubercular agents.
AID259392Inhibitory activity against KasA from Mycobacterium tuberculosis H37Rv2006Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1
Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli.
AID427049Binding affinity to Escherichia coli KAS3 expressed in Escherichia coli BL21 (DE3) by NMR analysis2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Antimicrobial natural products as beta-ketoacyl-acyl carrier protein synthase III inhibitors.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1625600Antibacterial activity against Francisella tularensis LVS after 18 to 24 hrs by Alamar blue dye-based colorimetric assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity.
AID697056Inhibition of Escherichia coli FabB2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
The lipogenesis pathway as a cancer target.
AID380450Antimicrobial activity against wild type Escherichia coli after 20 hrs2006Journal of natural products, Mar, Volume: 69, Issue:3
Discovery of bacterial fatty acid synthase inhibitors from a Phoma species as antimicrobial agents using a new antisense-based strategy.
AID1625602Antibacterial activity against methicillin-resistant Staphylococcus aureus BAA 1762 after 18 to 24 hrs by Alamar blue dye-based colorimetric assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity.
AID388055Antibacterial activity against Staphylococcus aureus Smith by agar dilution method2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Synthesis and biological activity of enantiomeric pairs of 5-[(E)-cycloalk-2-enylidenemethyl]thiolactomycin congeners.
AID590140Antitubercular activity against Mycobacterium tuberculosis H37Rv by microplate alamar blue assay2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Novel thiolactone-isatin hybrids as potential antimalarial and antitubercular agents.
AID345869Antimalarial activity against chloroquine-sensitive Plasmodium falciparum W2 by [3H]hypoxanthine uptake2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Targeting the fatty acid biosynthesis enzyme, beta-ketoacyl-acyl carrier protein synthase III (PfKASIII), in the identification of novel antimalarial agents.
AID104011Activity against Mycobacterium tuberculosis (H37Rv) using the standard BACTEC radiometric growth assay2000Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17
A new class of antituberculosis agents.
AID427044Antibacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3114 after 20 hrs by twofold serial broth dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Antimicrobial natural products as beta-ketoacyl-acyl carrier protein synthase III inhibitors.
AID40464Inhibitory activity against recombinant Mycobacterium tuberculosis beta-ketoacyl-Acyl Carrier Protein synthase mtFabH condensing enzyme2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Acetylene-based analogues of thiolactomycin, active against Mycobacterium tuberculosis mtFabH fatty acid condensing enzyme.
AID427045Antibacterial activity against Enterococcus faecalis KCTC 2011 after 20 hrs by twofold serial broth dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Antimicrobial natural products as beta-ketoacyl-acyl carrier protein synthase III inhibitors.
AID393130Antimicrobial activity against methicillin-resistant Staphylococcus aureus CCARM 3114 after 20 hrs by twofold serial broth dilution method2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Novel E. coli beta-ketoacyl-acyl carrier protein synthase III inhibitors as targeted antibiotics.
AID380449Antimicrobial activity against vancomycin-resistant Enterococcus faecium CL5791 after 20 hrs2006Journal of natural products, Mar, Volume: 69, Issue:3
Discovery of bacterial fatty acid synthase inhibitors from a Phoma species as antimicrobial agents using a new antisense-based strategy.
AID380451Antimicrobial activity against envA transfected Escherichia coli after 20 hrs2006Journal of natural products, Mar, Volume: 69, Issue:3
Discovery of bacterial fatty acid synthase inhibitors from a Phoma species as antimicrobial agents using a new antisense-based strategy.
AID259390Inhibitory activity against FabH from Mycobacterium tuberculosis H37Rv2006Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1
Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli.
AID474757Antimicrobial activity against chloroquine-resistant Plasmodium falciparum W22010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Comparison of the antiplasmodial and falcipain-2 inhibitory activity of beta-amino alcohol thiolactone-chalcone and isatin-chalcone hybrids.
AID1625607Cytotoxicity against human THP1 cells at < 100 ug/ml after 2 days by Alamar blue assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity.
AID309336Inhibition of Mycobacterium tuberculosis FabH2007Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
Synthesis and biological evaluation of a C5-biphenyl thiolactomycin library.
AID388056Antibacterial activity against Moraxella catarrhalis ATCC 25238 by agar dilution method2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Synthesis and biological activity of enantiomeric pairs of 5-[(E)-cycloalk-2-enylidenemethyl]thiolactomycin congeners.
AID393125Binding affinity to Escherichia coli K12 KAS 3 expressed in Escherichia coli BL21 by fluorescence quenching analysis2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Novel E. coli beta-ketoacyl-acyl carrier protein synthase III inhibitors as targeted antibiotics.
AID427046Antibacterial activity against Staphylococcus aureus KCTC 1621 after 20 hrs by twofold serial broth dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Antimicrobial natural products as beta-ketoacyl-acyl carrier protein synthase III inhibitors.
AID388058Inhibition of fatty acid synthase type 1 in human HepG2 cells assessed as [1-14C]acetate incorporation into cellular fatty acid2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Synthesis and biological activity of enantiomeric pairs of 5-[(E)-cycloalk-2-enylidenemethyl]thiolactomycin congeners.
AID697058Inhibition of FASN in human HepG2 cells2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
The lipogenesis pathway as a cancer target.
AID1625603Antibacterial activity against Yersinia pestis A1122 after 18 to 24 hrs by Alamar blue dye-based colorimetric assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity.
AID1625612Antibacterial activity against Klebsiella pneumoniae KPC2ST258 infected in Swiss Webster mouse assessed as survival time at 100 mg/kg, sc administered 1, 12 and 24 hrs post infection measured every 12 hrs for 7 days2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity.
AID634359Antimicrobial activity against vancomycin-resistant Enterococcus faecium clinical isolate after 20 hrs by 2 fold serial broth dilution method2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Discovery of novel selective inhibitors of Staphylococcus aureus β-ketoacyl acyl carrier protein synthase III.
AID634363Cytotoxicity against mouse NIH/3T3 cells assessed as cell survival at 100 nM after 24 hrs by MTT assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Discovery of novel selective inhibitors of Staphylococcus aureus β-ketoacyl acyl carrier protein synthase III.
AID1625606Binding affinity to Mycobacterium tuberculosis wild type FabB expressed in Mycobacterium smegmatis MC2 155 by WaterLOGSY-based competition assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity.
AID697057Inhibition of FASN in rat liver2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
The lipogenesis pathway as a cancer target.
AID590136Antiplasmodial activity against Plasmodium falciparum W22011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Novel thiolactone-isatin hybrids as potential antimalarial and antitubercular agents.
AID259387Inhibitory activity against Mycobacterium tuberculosis H37Rv2006Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1
Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli.
AID345868Inhibition of Plasmodium falciparum KAS3 expressed in Escherichia coli assessed as transfer of [1-14C]acetyl-CoA to [1-14C]acetyl-ACP2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Targeting the fatty acid biosynthesis enzyme, beta-ketoacyl-acyl carrier protein synthase III (PfKASIII), in the identification of novel antimalarial agents.
AID393124Binding affinity to Escherichia coli K12 KAS 3 expressed in Escherichia coli BL21 by STD-NMR spectroscopy2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Novel E. coli beta-ketoacyl-acyl carrier protein synthase III inhibitors as targeted antibiotics.
AID308071Antimicrobial activity against Bacteroides fragilis GAI55602007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
Synthesis and biological activity of enantiomeric pairs of 5-vinylthiolactomycin congeners.
AID474758Inhibition of recombinant Plasmodium falciparum falcipain-22010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Comparison of the antiplasmodial and falcipain-2 inhibitory activity of beta-amino alcohol thiolactone-chalcone and isatin-chalcone hybrids.
AID252272Maximum amount of weight loss in Balb/C mice after 7 days of 60 mg/kg intraperitoneal administration2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase.
AID393126Antimicrobial activity against Escherichia coli KCTC 1682 after 20 hrs by twofold serial broth dilution method2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Novel E. coli beta-ketoacyl-acyl carrier protein synthase III inhibitors as targeted antibiotics.
AID1625597Binding affinity to Mycobacterium tuberculosis wild type FabB expressed in Mycobacterium smegmatis MC2 155 by intrinsic tryptophan fluorescence quenching-based fluorimetric method2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity.
AID427050Antibacterial activity against vancomycin-resistant Enterococcus faecalis clinical isolates after 20 hrs by twofold serial broth dilution method2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Antimicrobial natural products as beta-ketoacyl-acyl carrier protein synthase III inhibitors.
AID308070Antimicrobial activity against Haemophilus influenzae IID9832007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
Synthesis and biological activity of enantiomeric pairs of 5-vinylthiolactomycin congeners.
AID1625598Binding affinity to Mycobacterium tuberculosis FabB C171Q mutant expressed in Mycobacterium smegmatis MC2 155 by intrinsic tryptophan fluorescence quenching-based fluorimetric method2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity.
AID393127Antimicrobial activity against Klebsiella pneumoniae KCTC 2242 after 20 hrs by twofold serial broth dilution method2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Novel E. coli beta-ketoacyl-acyl carrier protein synthase III inhibitors as targeted antibiotics.
AID380447Antimicrobial activity against methicillin-resistant Staphylococcus aureus COL after 20 hrs2006Journal of natural products, Mar, Volume: 69, Issue:3
Discovery of bacterial fatty acid synthase inhibitors from a Phoma species as antimicrobial agents using a new antisense-based strategy.
AID308072Inhibition of type1 FAS in HepG2 cells2007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
Synthesis and biological activity of enantiomeric pairs of 5-vinylthiolactomycin congeners.
AID1625613Antibacterial activity against Burkholderia pseudomallei after 18 to 24 hrs by Alamar blue dye-based colorimetric assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity.
AID1625599Antibacterial activity against Mycobacterium tuberculosis H37Rv after 6 days by Alamar blue dye-based colorimetric assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2001The Journal of biological chemistry, Mar-02, Volume: 276, Issue:9
Inhibition of beta-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin. Structure and mechanism.
AID1811Experimentally measured binding affinity data derived from PDB2001The Journal of biological chemistry, Mar-02, Volume: 276, Issue:9
Inhibition of beta-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin. Structure and mechanism.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2007Acta crystallographica. Section D, Biological crystallography, Dec, Volume: 63, Issue:Pt 12
Structure-assisted discovery of an aminothiazole derivative as a lead molecule for inhibition of bacterial fatty-acid synthesis.
AID1811Experimentally measured binding affinity data derived from PDB2007Acta crystallographica. Section D, Biological crystallography, Dec, Volume: 63, Issue:Pt 12
Structure-assisted discovery of an aminothiazole derivative as a lead molecule for inhibition of bacterial fatty-acid synthesis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2013The Journal of biological chemistry, Nov-22, Volume: 288, Issue:47
Structural basis for the recognition of mycolic acid precursors by KasA, a condensing enzyme and drug target from Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (99)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (10.10)18.7374
1990's14 (14.14)18.2507
2000's51 (51.52)29.6817
2010's23 (23.23)24.3611
2020's1 (1.01)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (6.06%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other93 (93.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]